J
Jamil Asselah
Publications - 1
Citations - 1630
Jamil Asselah is an academic researcher. The author has contributed to research in topics: Survival rate & Hepatocellular carcinoma. The author has an hindex of 1, co-authored 1 publications receiving 987 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.